Center for Cancer Biology
Science directors: Jean-Christophe Marine & Diether Lambrechts
Our research is focused on the interaction between cancer cells and the tumor microenvironment at an (epi)genetic, metabolic and phenotypic level. This places CCB in a unique position to develop novel insights and (combination) therapies considering the complexity and heterogeneous nature of the tumor ecosystem and targeting the cancer cells, TME, and/or interplay between these two components. Part of our mission is to identify more accurate biomarkers and methodologies that will revolutionize pathology. By going beyond the canonical bench-to-beside model and developing a bed-to-bench-and-back approach, we put the patients at the core of our integrative efforts.
Labs
Name
Function
VIB Group Leader / Expert
Extra info
VIB-KU Leuven Center for Cancer Biology
Function
VIB Group Leader / Expert
Extra info
VIB-KU Leuven Center for Cancer Biology
Name
Function
VIB Group Leader / Expert
Extra info
VIB-KU Leuven Center for Cancer Biology
Name
Function
VIB Group Leader / Expert
Extra info
VIB-KU Leuven Center for Cancer Biology
Name
Function
VIB Group Leader / Expert
Extra info
VIB-KU Leuven Center for Cancer Biology
Name
Function
VIB Group Leader / Expert
Extra info
VIB-KU Leuven Center for Cancer Biology
Name
Function
VIB Group Leader / Expert
Extra info
VIB-KU Leuven Center for Cancer Biology
Name
Function
VIB Group Leader / Expert
Extra info
VIB-KU Leuven Center for Cancer Biology
Name
Function
VIB Group Leader / Expert
Extra info
VIB-KU Leuven Center for Cancer Biology
Name
Function
VIB Group Leader / Expert
Extra info
VIB-KU Leuven Center for Cancer Biology
Name
Function
VIB Group Leader / Expert
Extra info
VIB-KU Leuven Center for Cancer Biology
Name
Function
VIB Group Leader / Expert
Extra info
VIB-KU Leuven Center for Cancer Biology
Name
Function
VIB Group Leader / Expert
Extra info
VIB-KU Leuven Center for Cancer Biology
Impact on society
Toward new cancer medicines
Medulloblastoma is a rare, life-threatening brain tumor that mainly affects children. Research carried out by Peter Carmeliet (VIB-KU Leuven) and colleagues provided the basis for a new potential drug: TB-403.
Read more
Personalized immunotherapy in cancer patients
Improving treatment outcome prediction by characterizing the tumor and tumor micro-environment at single-cell level during treatment with immune-checkpoint blockers in the Pointillism project.
Read more
Improving liver disease diagnosis
Overcoming the main current diagnostic challenges in hepatology practice in the liver project.
Read more
Contagious
An in-dept characterization of the dynamic immune response to coronavirus SARS-CoV-2 in the Contagious project.
Read more